Cerus Co. (NASDAQ:CERS) CFO Sells $46,722.00 in Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 31,148 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $1.50, for a total value of $46,722.00. Following the sale, the chief financial officer now owns 935,754 shares of the company’s stock, valued at approximately $1,403,631. The trade was a 3.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kevin Dennis Green also recently made the following trade(s):

• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The stock was sold at an average price of $1.58, for a total value of $95,836.48.

Cerus Trading Down 2.6 %

Shares of CERS stock traded down $0.04 during trading hours on Monday, reaching $1.47. The company had a trading volume of 1,812,528 shares, compared to its average volume of 1,306,882. The company has a 50 day moving average of $1.74 and a 200 day moving average of $1.79. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The firm has a market cap of $273.11 million, a price-to-earnings ratio of -13.36 and a beta of 1.56. Cerus Co. has a 1-year low of $1.38 and a 1-year high of $2.54.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $50.81 million for the quarter, compared to analysts’ expectations of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. On average, equities research analysts anticipate that Cerus Co. will post -0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.

Hedge Funds Weigh In On Cerus

A number of hedge funds and other institutional investors have recently made changes to their positions in CERS. Rockport Wealth LLC acquired a new position in shares of Cerus in the fourth quarter valued at approximately $25,000. Cibc World Markets Corp acquired a new position in shares of Cerus in the fourth quarter valued at approximately $26,000. R Squared Ltd acquired a new position in shares of Cerus in the fourth quarter valued at approximately $29,000. Virtu Financial LLC acquired a new position in shares of Cerus in the fourth quarter valued at approximately $33,000. Finally, Dark Forest Capital Management LP acquired a new position in shares of Cerus in the fourth quarter valued at approximately $34,000. 78.37% of the stock is owned by institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.